Skip to main content

Table 1 Baseline Characteristics in Subjects with malignancy and ascites stratified by presence of hepatic metastasis

From: Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites

Variable

Without liver metastasis 119 subjects

With liver metastasis 122 subjects

P Value

Portal hypertension*

39/119 (33%)

30/122 (24%)

0.2

Sinusoidal portal hypertension*

4/119 (3%)

9/122 (7%)

0.3

Peritoneal carcinomatosis (PC)*

73/119 (61%)

77/122 (63%)

0.8

Chylous ascites

8/119 (7%)

6/122 (5%)

0.6

SAAG < 1.1 and total protein < 2.5

7/119 (3.5%)

15/122 (12%)

0.1

SAAG < 1.1 and total protein < 2.5 with no evidence of PC on cytology and or imaging

1/119 (0.84%)

1/122 (0.82%)

1

Portal hypertension without PC**

16/119 (13%)

7/122 (6%)

0.04

Sinusoidal portal hypertension without PC**

2/119 (2%)

2/122 (2%)

1

PC based on positive cytology and or imaging

85/119 (71%)

105/122 (86%)

0.007

PC without evidence of PC on cytology or imaging±

18/119 (15%)

10/122 (8%)

0.1

Mixed pattern (High SAAG and evidence of PC on cytology and or imaging)

23/119 (19.3%)

23/122 (18.8%)

1

Primary malignancy location

 Breast cancer

12/119 (10%)

29/122 (24%)

0.006

 Gastric cancer

24/119 (20%)

9/122 (7%)

0.005

 Lung cancer

32/119 (27%)

16/122 (13%)

0.009

 Ovarian cancer

15/119 (13%)

5/122 (4%)

0.02

 Pancreatic cancer

14/119 (12%)

26/122 (21%)

0.06

 Renal cancer

13/119 (11%)

13/122 (11%)

1

 Colon cancer

9/119 (8%)

24/122 (20%)

0.008

Treatment regimen

   

 Diuretics#

21/119 (18%)

24/122 (20%)

0.7

 Paracentesis#

18/119 (15%)

40/122 (33%)

0.001

 Peritoneal drain#

35/119 (29%)

19/122 (16%)

0.01

 Shunt#

1/119 (1%)

0/122 (0%)

0.5

 Chemotherapy/immunotherapy

44/119 (37%)

39/122 (32%)

0.4

  1. * Subjects with portal hypertension, sinusoidal portal hypertension and peritoneal carcinomatosis based on ascites fluid analysis
  2. ** Subjects with PH and SPH based on ascites fluid analysis who had no evidence of PC
  3. on cytology or imaging
  4.  ± Subjects who met criteria for PC based on ascites fluid analysis but did not have demonstrable PC on imaging or positive cytology
  5. # Subjects received these treatments in addition to Chemotherapy/immunotherapy